Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Garenoxacin - FUJIFILM Toyama Chemical

Drug Profile

Garenoxacin - FUJIFILM Toyama Chemical

Alternative Names: BMS-284756; Des-F(6)-quinolone; Desquinolone; Garenoxacin mesylate; Geninax; Inforce; T-3811; T-3811-ME

Latest Information Update: 29 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taisho Pharmaceutical; Toyama Chemical
  • Developer FUJIFILM Toyama Chemical; Merck & Co; Taisho Pharmaceutical; Toyama Chemical
  • Class Antibacterials; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gram-negative infections; Gram-positive infections; Otorhinolaryngological infections; Respiratory tract infections
  • Preregistration Bacterial infections
  • Discontinued Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Intra-abdominal infections; Skin and soft tissue infections

Most Recent Events

  • 01 Oct 2018 Taisho Toyama Pharmaceutical returns marketing rights to FUJIFILM Toyama Chemical
  • 16 Sep 2016 Astellas Pharma in collaboration with Taisho Toyama Pharmaceutical completes the GARIREO study for Respiratory tract infections in Japan (PO) (UMIN000016373)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Bacterial-infections in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top